The vision and Team behind ImmuneWatch

ImmuneWatch group picture in the office featuring Kris Laukens, Sander Wuyts, Benson Ogunjimi, Max Van Houcke, Pieter Meysman and Tom Bosschaerts

Our story

ImmuneWatch’s core mission is to crack one of the longest running challenges in systems immunology: predicting T-cell specificity with machine learning.

This journey started at the University of Antwerp and Antwerp University Hospital in Belgium when immunologists teamed up with biodata scientists within the AUDACIS consortium. The team pioneered the first work on using machine learning for TCR-epitope specificity predictions. Meanwhile, this collaboration led to more than 30 publications in the field of computational immunology.

Based on this success, ImmuneWatch was founded as a spin-off company and has since then significantly improved the technology, establishing themselves as world leaders in the field of TCR-epitope predictions.

The Team

The ImmuneWatch team unites a diverse range of experts, all driven by a shared mission: Annotating the epitope-specificity of TCRs.

Entrepreneur and PhD in Bioscience Engineering with speciality in bioinformatics


Got his 10 minutes of worldwide fame when he found a bitcoin in synthetic DNA.

LinkedIn

Sander Wuyts, PhD
Chief Executive Officer

PhD in Bioscience Engineering with speciality in machine learning and immunoinformatics.

Chan Zuckerberg-initiative grantee for T-cell bioinformatics

LinkedIn

prof. Pieter Meysman, PhD
Chief Technical Officer

Biodata science and R&D manager in the life science industry.

PhD in Bioscience Engineering with speciality in infectious diseases and immunology.

LinkedIn

Tom Bosschaerts, PhD
Chief Operation Officer

Professor in bioinformatics and biodata mining at Laukens lab.

Winner of the AstraZeneca Foundation 2021 Award for his work on heterogeneity of immune defenses to infections.

LinkedIn

prof. Kris Laukens, PhD
Scientific Director

Associate Professor in Translational Immunology and paediatric rheumatologist at the Antwerp University Hospital

ERC Starting Grant awardee for modelling population T-cell responses

prof. Benson Ogunjimi, MD, PhD
Medical Director

Machine learning expert with a new profound love for immunology

Developer of the immunoinformatics tool ClusTCR and a Live Tennis Scores app: Aced

LinkedIn

Max Van Houcke
Data Scientist

Partnerships

ImmuneWatch is striving for excellence in its field and recognises the importance of strong strategic collaborations to achieve their goals.

Project partner in Yellow4FLAVI

Our scientific quest is to uncover the secrets of immunity conferred by the Yellow Fever virus YF17D vaccine. By deciphering these mechanisms, Yellow4FLAVI aims to lay the groundwork for the development of more effective and targeted flavivirus vaccines, addressing current and future health emergencies.

Launched at the start of 2024, ImmuneWatch will work together with:

Project partner in Yellow4FLAVI

Our scientific quest is to uncover the secrets of immunity conferred by the Yellow Fever virus YF17D vaccine. By deciphering these mechanisms, Yellow4FLAVI aims to lay the groundwork for the development of more effective and targeted flavivirus vaccines, addressing current and future health emergencies.

Launched at the start of 2024, ImmuneWatch will work together with:

Project partner in Yellow4FLAVI

Our scientific quest is to uncover the secrets of immunity conferred by the Yellow Fever virus YF17D vaccine. By deciphering these mechanisms, Yellow4FLAVI aims to lay the groundwork for the development of more effective and targeted flavivirus vaccines, addressing current and future health emergencies.

Launched at the start of 2024, ImmuneWatch will work together with:

Project partner in CAPTIVATE

CAPTIVATE, a new innovative European partnership to tackle hurdles in malaria vaccine development. With cutting-edge technologies and an unwavering commitment, the EU-funded CAPTIVATE project has the mission to create a next-generation malaria vaccine that targets multiple stages of the deadliest malaria parasite, P. falciparum.

Launched end of 2023, ImmuneWatch will work together with:

Project partner in CAPTIVATE

CAPTIVATE, a new innovative European partnership to tackle hurdles in malaria vaccine development. With cutting-edge technologies and an unwavering commitment, the EU-funded CAPTIVATE project has the mission to create a next-generation malaria vaccine that targets multiple stages of the deadliest malaria parasite, P. falciparum.

Launched end of 2023, ImmuneWatch will work together with:

Project partner in CAPTIVATE

CAPTIVATE, a new innovative European partnership to tackle hurdles in malaria vaccine development. With cutting-edge technologies and an unwavering commitment, the EU-funded CAPTIVATE project has the mission to create a next-generation malaria vaccine that targets multiple stages of the deadliest malaria parasite, P. falciparum.

Launched end of 2023, ImmuneWatch will work together with:

Quantoom Biosciences and the University of Antwerp.

Early 2023, ImmuneWatch entered into a public-private partnership with Quantoom Biosciences and the University of Antwerp. The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process. It is believed that the proposed methodology could reduce time and expenditures in the preclinical development process of vaccines. As a proof-of-concept, the team has chosen to work on a rabies vaccine candidate.

Quantoom Biosciences and the University of Antwerp.

Early 2023, ImmuneWatch entered into a public-private partnership with Quantoom Biosciences and the University of Antwerp. The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process. It is believed that the proposed methodology could reduce time and expenditures in the preclinical development process of vaccines. As a proof-of-concept, the team has chosen to work on a rabies vaccine candidate.

Quantoom Biosciences and the University of Antwerp.

Early 2023, ImmuneWatch entered into a public-private partnership with Quantoom Biosciences and the University of Antwerp. The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process. It is believed that the proposed methodology could reduce time and expenditures in the preclinical development process of vaccines. As a proof-of-concept, the team has chosen to work on a rabies vaccine candidate.

Find the epitope-specificity of your TCRs today